Related Experiment Video
Updated: Jan 30, 2026

Plaquing of Herpes Simplex Viruses
Published on: November 5, 2021
Herpes simplex risk during biologic treatment for erythrodermic psoriasis
Shree V Dhotre1, Pradnya S Dhotre2, Basavraj S Nagoba3
1Department of Microbiology, Ashwini Rural Medical College, Hospital and Research Centre, Solapur 413006, Maharashtra, India. shree_v_dhotre@yahoo.co.in.
Abstract:
Disseminated herpes simplex virus infection in erythrodermic psoriasis remains exceedingly uncommon, yet it poses substantial diagnostic and therapeutic challenges in patients receiving biologic therapy. The recent case by Berjawi et al illustrates an atypical presentation of widespread herpes simplex virus-1 in a patient undergoing treatment with ixekizumab and topical corticosteroids, highlighting diagnostic uncertainty, cumulative immunosuppression, and therapeutic decision-making in severe psoriasis. This correspondence aims to emphasize the challenges of early herpes simplex virus recognition, discuss the potential but associative role of interleukin-17 inhibition in antiviral defence, and underscore the lack of clinical guidance regarding interruption and safe reintroduction of biologic therapy following viral clearance.
Related Concept Videos
Relative Risk
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
What is Conservation Biology?
Factors Affecting the Risk of Infection
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...
Biological Effects of Radiation
Synthetic Biology
Golden rice
Golden rice is a genetically modified...

